EntryPoint Capital LLC acquired a new stake in 10x Genomics (NASDAQ:TXG - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 48,137 shares of the company's stock, valued at approximately $420,000.
Other institutional investors and hedge funds have also bought and sold shares of the company. GAMMA Investing LLC raised its stake in 10x Genomics by 81.8% in the 1st quarter. GAMMA Investing LLC now owns 3,586 shares of the company's stock valued at $31,000 after acquiring an additional 1,614 shares during the period. Invesco Ltd. raised its stake in 10x Genomics by 21.8% in the 4th quarter. Invesco Ltd. now owns 118,067 shares of the company's stock valued at $1,695,000 after acquiring an additional 21,134 shares during the period. Deutsche Bank AG raised its stake in 10x Genomics by 35.3% in the 4th quarter. Deutsche Bank AG now owns 10,190 shares of the company's stock valued at $146,000 after acquiring an additional 2,657 shares during the period. Cetera Investment Advisers raised its stake in 10x Genomics by 22.7% in the 4th quarter. Cetera Investment Advisers now owns 19,898 shares of the company's stock valued at $286,000 after acquiring an additional 3,679 shares during the period. Finally, Rhumbline Advisers raised its stake in 10x Genomics by 11.4% in the 1st quarter. Rhumbline Advisers now owns 120,490 shares of the company's stock valued at $1,052,000 after acquiring an additional 12,374 shares during the period. 84.68% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
A number of brokerages recently issued reports on TXG. Morgan Stanley lowered their price objective on 10x Genomics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 12th. Deutsche Bank Aktiengesellschaft set a $14.00 price objective on 10x Genomics and gave the company a "hold" rating in a research note on Friday, August 8th. Bank of America boosted their price objective on 10x Genomics from $12.00 to $13.00 and gave the company a "neutral" rating in a research note on Thursday, June 26th. Wall Street Zen upgraded 10x Genomics from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of 10x Genomics in a research report on Thursday, August 14th. Six analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $13.54.
Get Our Latest Stock Report on TXG
10x Genomics Stock Up 9.2%
Shares of TXG stock traded up $1.20 during trading on Friday, hitting $14.30. The company had a trading volume of 3,446,087 shares, compared to its average volume of 3,399,679. The stock's 50-day moving average is $12.59 and its two-hundred day moving average is $10.65. The stock has a market capitalization of $1.78 billion, a price-to-earnings ratio of -20.43 and a beta of 2.03. 10x Genomics has a 52 week low of $6.78 and a 52 week high of $24.76.
10x Genomics (NASDAQ:TXG - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.63. The company had revenue of $172.91 million for the quarter, compared to analysts' expectations of $139.36 million. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. 10x Genomics's revenue for the quarter was up 12.9% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.32) earnings per share. 10x Genomics has set its Q3 2025 guidance at EPS. On average, research analysts predict that 10x Genomics will post -1.43 EPS for the current fiscal year.
10x Genomics Company Profile
(
Free Report)
10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.
See Also
Before you consider 10x Genomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 10x Genomics wasn't on the list.
While 10x Genomics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access